Key transaction
Director Heidi Hagen of Vericel Corp (NASDAQ: VCEL) sold 15,000 shares of the company’s common stock on March 23, 2026, at $32.41 per share, producing proceeds of $486,149, according to a Form 4 filed with the Securities and Exchange Commission. The filing indicates the sale was executed under a Rule 10b5-1 trading plan that Hagen adopted on November 14, 2024.
Following the disposition, Hagen is reported to directly hold 31,850 shares of Vericel common stock.
Concurrent option activity
On the same day as the sale, Hagen exercised options to acquire 15,000 shares at an exercise price of $2.76, representing $41,400 in exercise cost. These options were granted on May 4, 2016, and are exercisable in monthly installments. The options would otherwise expire on May 4, 2026.
Share-price context
The sale occurred while Vericel’s share price was trading near a 52-week low of $29.24; the stock has declined 31% over the past 12 months. Market participants may view insider transactions through multiple lenses, and the transaction here coincides with option exercise activity that was already set to lapse under the stated terms.
Operational and financial backdrop
Vericel announced fourth-quarter 2025 results that exceeded consensus estimates, reporting earnings per share of $0.45 versus a $0.39 forecast, and revenue of $92.9 million compared with an expected $90.71 million. For the full year, MACI revenue reached $239.5 million, a 21% increase from the prior year.
Those results prompted analyst updates. H.C. Wainwright raised its price target on Vericel to $64 from $60 while maintaining a Buy rating. Separately, Leerink Partners reiterated an Outperform rating and set a price target of $46.
Regulatory and capacity developments include FDA approval for Vericel to start commercial production of MACI at its new cell therapy facility in Burlington, Massachusetts. Commercial production at that site is scheduled to begin in the second quarter of 2026.
Valuation signals highlighted by data services
Data from an investing-research service included with the filing notes a $1.57 billion market capitalization for Vericel and places the company on a Most Undervalued list. The same service cites a Piotroski Score of 9 for Vericel, flagged as one of 12 exclusive tips available to subscribers.
What the record shows
The public filings document three linked items on March 23, 2026: a sale of 15,000 shares executed through a prearranged Rule 10b5-1 plan; the exercise of 15,000 options originally granted in 2016; and an updated ownership report showing 31,850 shares held directly by Hagen. Separately, corporate results and regulatory milestones reported for 2025 and early 2026 show revenue growth and preparations to scale MACI production in a new facility.
This article presents the transactions and company disclosures as reported in SEC filings and company announcements. It does not assess motivations beyond what the filings and the company’s public disclosures state.